


# PRODUCT INFORMATION



## Cilastatin

Item No. 23511

**CAS Registry No.:** 82009-34-5  
**Formal Name:** (2Z)-7-[[[(2R)-2-amino-2-carboxyethyl]thio]-2-[[[(1S)-2,2-dimethylcyclopropyl]carbonyl]amino]-2-heptenoic acid  
**MF:** C<sub>16</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>S  
**FW:** 358.5  
**Purity:** ≥98%  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Cilastatin is supplied as a crystalline solid. A stock solution may be made by dissolving the cilastatin in the solvent of choice, which should be purged with an inert gas. Cilastatin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of cilastatin in these solvents is approximately 12.5 mg/ml.

### Description

Cilastatin is an inhibitor of dipeptidase (dehydropeptidase I), a renal dipeptidase.<sup>1</sup> It inhibits human renal dipeptidase ( $K_i = 0.7 \mu\text{M}$ ), porcine dipeptidase ( $\text{IC}_{50} = 0.11 \mu\text{M}$ ), and bacterial metallo- $\beta$ -lactamase CphA from *A. hydrophila* ( $\text{IC}_{50} = 178 \mu\text{M}$ ).<sup>1-3</sup> Cilastatin (200  $\mu\text{g/ml}$ ) protects primary porcine renal proximal tubular epithelial cells from nephrotoxicity and apoptosis induced by vancomycin (Item No. 15327).<sup>4</sup> In a mouse model of systemic infection, cilastatin in combination with imipenem (Item No. 16039) protects mice from *S. aureus*, *E. coli*, and *P. aeruginosa* infection.<sup>5</sup> Cilastatin was designed to inhibit renal metabolism of imipenem and prolong its half-life.<sup>2</sup> Formulations containing cilastatin in combination with imipenem have been used to treat susceptible bacterial infections.

### References

1. Campbell, B.J., Forrester, L.J., Zahler, W.L., *et al.* Beta-lactamase activity of purified and partially characterized human renal dipeptidase. *J. Biol. Chem.* **259**(23), 14586-14590 (1984).
2. Kahan, F.M., Kropp, H., Sundelof, J.G., *et al.* Thienamycin: Development of imipenem-cilastatin. *J. Antimicrob. Chemother.* **12**(Suppl. D), 1-35 (1983).
3. Keynan, S., Hooper, N.M., Felici, A., *et al.* The renal membrane dipeptidase (dehydro-peptidase I) inhibitor, cilastatin, inhibits the bacterial metallo- $\beta$ -lactamase enzyme CphA. *Antimicrob. Agents Chemother.* **39**(7), 1629-1631 (1995).
4. Humanes, B., Jado, J.C., Camaño, S., *et al.* Protective effects of cilastatin against vancomycin-induced nephrotoxicity. *Biomed Res. Int.* 704382 (2015).
5. Petersen, P.J., Jacobus, N.V., Weiss, W.J., *et al.* *In vitro* and *in vivo* activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I. *Antimicrob. Agents Chemother.* **35**(1), 203-207 (1991).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/21/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM